Latest Content

Patients with HPV-associated oropharyngeal cancer who received 23% less radiation reported fewer swallowing, voice and dry mouth problems six months after treatment.

Heather Curley discusses her leptomeningeal disease diagnosis, joining an experimental vaccine trial and the milestones she has been able to share with her daughter.

A phase 3 trial presented at ASTRO 2026 found that giving focused radiation in three to five sessions, instead of one, lowered the chance of cancer returning at the surgery site, and patients lived longer.

A new radiation implant placed during surgery for brain metastases nearly stopped tumors from returning and doubled survival, a new study found.

Six years after being diagnosed with B-cell ALL at 21, William Yank opens up about the physical changes of treatment, the emotional weight of constant care and the role hope plays in his survivorship.

Long-term results presented at ASTRO 2026 show that a shorter radiation schedule after mastectomy controls high-risk breast cancer as well as the standard five-week course, without more long-term side effects.

FDA fast-tracks review of elinzanetant for hot flashes linked to breast cancer treatment. Here’s what the trial found and what patients should know.

After two relapses, CAR T-cell therapy and a stem cell transplant, William Yank is in remission. But infertility, mental health challenges and a changed sense of self followed him into survivorship.

A phase 3 trial found proton therapy did not help people with advanced liver cancer live longer than standard photon radiation therapy.

Some patients with lymphoma show no detectable cancer by day 8 of treatment, and a lymphoma specialist explains how early testing could guide care.

Life after cancer can bring lasting physical, financial and emotional challenges, especially for young survivors navigating life after treatment.

Dr. Maurie Markman discusses how AI could support primary care doctors and specialists caring for patients with cancer while keeping physicians at the center.

A combination of Zenbexus, Darzalex and dexamethasone nearly doubled the rate of deep, MRD-negative responses in relapsed multiple myeloma.